From: <u>Deborah J. Bortot</u>
To: <u>Teresa L. Williamson</u>

Subject: FW: Representative Tom Price

Date: Friday, December 16, 2016 1:10:00 PM

From: Ann M Donaldson

Sent: Friday, December 16, 2016 12:56 PM

To: Deborah J. Bortot

Cc: James Carroll; Katja Bullock **Subject:** Representative Tom Price

Good afternoon,

The Public Financial Disclosure Report (OGE-278) for Tom Price is now available for your review in *Integrity* regarding a possible nomination by the President-Elect to be Secretary of the Department of Health and Human Services.

Because Representative Price has not been formally nominated, please treat the identity and contents of the report confidentially, unless and until the Presidential Transition Team makes an official announcement.

Representative Price can be reached via Stefan Passatino of Dentons at

Please begin your review of the report and coordinate with our office as soon as possible. The Presidential Transition Team contact currently assigned to this matter is Jim Carroll. Mr. Carroll can be reached at or by email at or b

Thank you,

Presidential Transition Team

Ann M. Donaldson
Associate

JONES DAY® - One Firm Worldwide[™]
51 Louisiana Avenue, NW
Washington, DC 20001
Office +

========

This e-mail (including any attachments) may contain information that is private, confidential, or protected by attorney-client or other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail, so that our records can be corrected.

From: Sandra S. Mabry
To: Teresa L. Williamson

Subject: RE: OGE Reports for Trump Nominees

Date: Monday, December 19, 2016 6:31:10 PM

I spoke to him this afternoon. Sandy

From: Teresa L. Williamson

Sent: Monday, December 19, 2016 3:14 PM

To: Sandra S. Mabry

Subject: FW: OGE Reports for Trump Nominees

HEALTH

Committee



Chung Shek (chief clerk)

Liz Hackett (deputy clerk)



From: Shek, Chung (HELP Committee) Sent: Monday, December 19, 2016 1:42 PM

To: Teresa L. Williamson


Subject: OGE Reports for Trump Nominees

Hey Teresa,

Wanted to check in to see if there was a status on the OGE reports for any of the upcoming Trump nominees. We're looking for Price, DeVos, and Puzder.

Thanks!

Chung



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov] Sent: Tuesday, December 27, 2016 7:49 AM

To: Hall, Randall (HHS/OGC)
Cc: Olesh, Stanley D. (HHS/OGC)
Subject: RE: Secretary report

Good morning,

Following up on my message below. Thanks!

--Patrick

From: Patrick J. Lightfoot

Sent: Thursday, December 22, 2016 8:09 AM

To: 'Hall, Randall (HHS/OGC)'
Cc: Olesh, Stanley D. (HHS/OGC)
Subject: RE: Secretary report

Hi Randy and Stan,

Just wanted to check in and see if you'd been able to touch base with the filer's representative.

Thanks!

--Patrick



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov]
Sent: Tuesday, December 20, 2016 4:39 PM

To: Hall, Randall (HHS/OGC) **Subject:** RE: Secretary report

Randy,

Kim had mentioned you did not have the filer representative's contact information for the Secretary report. The representative's name is Stefan Passatino at Dentons. His phone number is

Also, the Transition Team POC is Jim Carroll, who can be reached at or at

--Patrick

From: Patrick J. Lightfoot

Sent: Tuesday, December 20, 2016 2:13 PM

To: 'Hall, Randall (HHS/OGC)' **Subject:** RE: Secretary report

Randy,

I've just submitted my first set of confirmations, questions, and edits in Integrity. There are a decent number of general comments as well as individual line item comments. One change I did make without adding a comment as I was going through was

Please let me know if you have any questions as you and the filer/filer's representative review.

Thanks!

--Patrick





From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov] Sent: Monday, December 19, 2016 12:58 PM

To: Hall, Randall (HHS/OGC) **Subject:** RE: Secretary report

Hi Randall,

I'm in the process of doing my initial review of the report. Quick question in light of the upcoming holidays: Will you be out of the office at all over the next few weeks? If so, could you send me the contact information of your back-up reviewer in your absence?

Thanks in advance! I look forward to working with you.

All the best,

Patrick

~ ~

Patrick J. Lightfoot Assistant Counsel, Ethics Law & Policy Branch General Counsel & Legal Policy Division

U.S. Office of Government Ethics 1201 New York Ave NW, Suite 500 Washington, DC 20005 Telephone: (202) 482-9271

Visit OGE's website: www.oge.gov

Follow OGE on Twitter: @OfficeGovEthics

From: Kimberly L. Sikora Panza

Sent: Monday, December 19, 2016 12:36 PM

To: 'Hall, Randall (HHS/OGC)'
Cc: Patrick J. Lightfoot
Subject: Secretary report

Hi Randy,

You mentioned to me that you rec'd the report for the potential nominee for Secretary, and inquired about the OGE POC. The OGE POC for this report is Patrick Lightfoot (cc:ed on this email) – his phone number is 202.482.9271.

Thanks, Kim

OGE Confidential Notice: This email, including all attachments, may constitute a Federal record or other Government property that is intended only for the use of the individual or entity to which it is addressed. This email also may contain information that is privileged, confidential, or otherwise protected from disclosure under applicable law. If you are not the intended recipient or the employee or agent responsible for delivering the transmission to the intended recipient, you are hereby notified that any dissemination, distribution, copying or use of this email or its contents is strictly prohibited. If you have received this email in error, please notify the sender by responding to the email and then immediately delete the email.

OGE Confidential Notice: This email, including all attachments, may constitute a Federal record or other Government property that is intended only for the use of the individual or entity to which it is addressed. This email also may contain information that is privileged, confidential, or otherwise protected from disclosure under applicable law. If you are not the intended recipient or the employee or agent responsible for delivering the transmission to the intended recipient, you are hereby notified that any dissemination, distribution, copying or use of this email or its contents is strictly prohibited. If you have received this email in error, please notify the sender by responding to the email and then immediately delete the email.

OGE Confidential Notice: This email, including all attachments, may constitute a Federal record or other Government property that is intended only for the use of the individual or entity to which it is addressed. This email also may contain information that is privileged, confidential, or otherwise protected from disclosure under applicable law. If you are not the intended recipient or the employee or agent responsible for delivering the transmission to the intended recipient, you are hereby notified that any dissemination, distribution, copying or use of this email or its contents is strictly prohibited. If you have received this email in error, please notify the sender by responding to the email and then immediately delete the email.

From: Passantino, Stefan C.
To: Olesh, Stanley D. (HHS/OGC)

Cc: Hall, Randall (HHS/OGC); Fischmann, Elizabeth (HHS/OGC); Silbaugh, Kathleen (HHS/OGC); Keane, Benjamin P.;


Cindy Berry; Patrick J. Lightfoot

Subject: RE: Public Financial Disclosure Report (OGE 278e form) [DEN-US_Active.FID13145093]


Date: Thursday, December 29, 2016 4:53:01 PM

Attachments: <u>image001.png</u>

Here are the answers to your questions. As noted below, we are currently in the process of updating the 278 via the Integrity system and that process will be completed shortly (if it isn't already complete). I am available at any time to discuss question 35. Stefan.











Stefan C. Passantino Partner

D + 1202 496 7756



Blog: www.paytoplaylawblog.com

Bio I Blog I Website

Chair, Dentons Political Law Practice

Dentons US LLP 1900 K Street, NW, Washington, DC 20006

Dentons US LLP 303 Peachtree Street, Suite 5300, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see <u>dentons.com</u> for Legal Notices.





From: Passantino, Stefan C.

Sent: Thursday, December 29, 2016 11:32 AM

To: Olesh, Stanley D. (HHS/OGC)

Cc: Hall, Randall (HHS/OGC); Fischmann, Elizabeth (HHS/OGC); Silbaugh, Kathleen

(HHS/OGC); Keane, Benjamin P.; Cindy Berry

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Yes, my understanding was that the contact we were to be working through at HHS would be out this week and that the discussions needed to wait until the first week of January. If that is incorrect, I am available to talk now. Also copied here is Cindy Berry who is working with Dr. Price on the Transition Team.



D Fax: +1 202 496 7756

M + (0) (5)

Blog: www.paytoplaylawblog.com

Bio I Blog I Website

Chair, **Dentons Political Law** Practice

Dentons US LLP 1900 K Street, NW, Washington, DC 20006

Dentons US LLP 303 Peachtree Street, Suite 5300, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see <u>dentons.com</u> for Legal Notices.

Referral to HHS

Referral to HHS			
Referral to HHS			









Referral to HHS		



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov]

Sent: Thursday, January 05, 2017 2:39 PM

To: Olesh, Stanley D. (HHS/OGC) Cc: Hall, Randall (HHS/OGC)

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Wanted to follow-up on my other question re: any changes Elizabeth might suggest to the EA. I' m planning to meet with Deb and Heather in an hour or so to discuss the version I' ve seen.



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov]

Sent: Thursday, January 05, 2017 10:17 AM

To: Olesh, Stanley D. (HHS/OGC) Cc: Hall, Randall (HHS/OGC)

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Apologies for the confusion. I addressed everything with respect to

Do you have an estimate on when you' ll receive comments from Elizabeth on the EA? We' re hoping to go over a solid first draft of the EA towards the end of the day today (even if the Innate issue is still being worked out).

Thanks for the answers to my last set of questions! I'm going to adjust those remaining alterations to the report shortly

(b)(3), (5), (6)

--Patrick



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov] Sent: Wednesday, January 04, 2017 5:11 PM

To: Olesh, Stanley D. (HHS/OGC) Cc: Hall, Randall (HHS/OGC)

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Hi Stan,

Attached are my comments/edits to the first draft of the EA. I realize mine may overlap with some of Elizabeth's, but I altered some paragraphs to conform more closely with the EA Guide. Please let me know if you have any questions.

--Patrick



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov] Sent: Wednesday, January 04, 2017 2:14 PM

To: Hall, Randall (HHS/OGC); Olesh, Stanley D. (HHS/OGC) Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Hi Randy and Stan,

Could one of you give me a call when you have a free moment? I' ve got two brief follow-up questions on the report and wanted to check on the status of the ethics agreement.

Thanks!

--Patrick

From: Patrick J. Lightfoot

Sent: Tuesday, January 03, 2017 9:15 AM

To: 'Olesh, Stanley D. (HHS/OGC)'

Cc: Hall, Randall (HHS/OGC); Fischmann, Elizabeth (HHS/OGC); Silbaugh, Kathleen (HHS/OGC)

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Stan,

Will do re: the CD. I agree on the technical side and will remove the corresponding entries in Part 1

accordingly.

As we had discussed beforehand,

If you or Randy could send a draft ethics agreement my way as soon as you can (despite the open question on that would be great.

Thanks! --Patrick



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov]

Sent: Friday, December 30, 2016 4:08 PM To: Olesh, Stanley D. (HHS/OGC) Cc: Hall, Randall (HHS/OGC)

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Stan,

Hope the conversation went well; this should help nail things down some. I' ll review the overall changes in Integrity first thing Tuesday and we' ll go from there.

Have a Happy New Year!

--Patrick

From: Passantino, Stefan C.

Sent: Friday, December 30, 2016 3:04 PM

To: Olesh, Stanley D. (HHS/OGC)

Cc: Hall, Randall (HHS/OGC); Fischmann, Elizabeth (HHS/OGC); Silbaugh, Kathleen (HHS/OGC); Keane, Benjamin P.;

Cindy Berry; Patrick J. Lightfoot

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Stanley, it was good speaking with you earlier today. I have had an opportunity to speak with Dr. Price and was able to confirm the issues we discussed. Specifically, I have confirmed the following:

(b)(3), (4), (5), (6)		

Stefan C. Passantino Partner

D + 1 202 496 7756

Blog: www.paytoplaylawblog.com


Bio I Blog I Website

Chair, Dentons Political Law Practice


Dentons US LLP 1900 K Street, NW, Washington, DC 20006 Dentons US LLP 303 Peachtree Street, Suite 5300, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see <u>dentons.com</u> for Legal Notices.



Rest of chain mentioned above



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov]

Sent: Thursday, January 05, 2017 2:39 PM

To: Olesh, Stanley D. (HHS/OGC)
Cc: Hall, Randall (HHS/OGC)

Subject: RE: Public Financial Disclosure Report (OGE 278e form)

Wanted to follow-up on my other question re: any changes Elizabeth might suggest to the EA. I'm planning to meet with Deb and Heather in an hour or so to discuss the version I've seen.

--Patrick



From: Passantino, Stefan C.

Sent: Monday, January 09, 2017 9:45 AM

To: Olesh, Stanley D. (HHS/OGC)

Cc: Fischmann, Elizabeth (HHS/OGC); Hall, Randall (HHS/OGC); Silbaugh, Kathleen (HHS/OGC); Keane, Benjamin P.; Cindy Berry; Patrick J. Lightfoot; Deborah J. Bortot; Weaver, Gretchen (NIH/OD) [E]; Caplan, Andrew (HHS/OGC)

Subject: RE: (b)(3), (6)

Good morning Stanley. I tried calling about this this morning. We would all like to try to get this to a resolution today if possible. If there is someone else I can speak with regarding this matter I am in my office and available. Thank you. Stefan.

Stefan C. Passantino Partner

> D +1 Fax: +1 202 496 7756 M + Fax: +1 202 496 7756

Blog: www.paytoplaylawblog.com

Bio I Blog I Website

Chair, **Dentons Political Law** Practice

Dentons US LLP 1900 K Street, NW, Washington, DC 20006 Dentons US LLP 303 Peachtree Street, Suite 5300, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see <u>dentons.com</u> for Legal Notices.

Referral to HHS	

Referral to HHS	

Referral to HHS	
Rest of chain mentioned above	



From: Passantino, Stefan C.

Sent: Monday, January 09, 2017 4:36 PM

To: Olesh, Stanley D. (HHS/OGC)

Cc: Hall, Randall (HHS/OGC); Keane, Benjamin P.

Subject: RE: 278 & draft Ethics Agreement [DEN-US_Active.FID13145093]

I have spoken with Dr. Price and we will make the requested changes to the 278 referenced by Patrick Lightfoot below. With respect to Part 6 and make the appropriate changes to reflect the accurate description.

(b)(3), (4), (5), (6)

Other than that, we are willing to sign this letter. Please advise whether Dr. Price is precleared by OGE. Thank you. Stefan.

Stefan C. Passantino Partner

| Fax: +1 202 496 7756



Bio I Blog I Website
Chair, Dentons Political Law Practice

Dentons US LLP 1900 K Street, NW, Washington, DC 20006

Dentons US LLP 303 Peachtree Street, Suite 5300, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see <u>dentons.com</u> for Legal Notices.



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov] Sent: Monday, January 09, 2017 2:41 PM

To: Olesh, Stanley D. (HHS/OGC) Cc: Hall, Randall (HHS/OGC)

Subject: RE:

Stan,

As discussed, below are the remaining questions/edits to the report we had on our end:



I've also attached a revised ethics agreement with changes made to the spousal employment paragraph (and a revised signature line with the filer's full name).

Thanks!

--Patrick





From: Passantino, Stefan C.

To: Olesh, Stanley D. (HHS/OGC)

Cc: Keane, Benjamin P.; Hall, Randall (HHS/OGC): Cindy Berry; Patrick J. Lightfoot; Jim Carroll

Subject: Re: Senate Questionnaire

Date: Wednesday, January 11, 2017 9:10:27 AM

Attachments: <u>image001.png</u>

image002.png image004.png 2 page attachment withheld in full - (b)(3), (4), (5), (6)

We will run this to ground and get back this morning I'm sure there is a solution here as we created both at the same time from the same source material.



From: Keane, Benjamin P.

Sent: Tuesday, January 10, 2017 6:38 PM

To: Olesh, Stanley D. (HHS/OGC); Passantino, Stefan C.

Cc: Hall, Randall (HHS/OGC); Cindy Berry

Subject: RE: 278 & draft Ethics Agreement [DEN-US Active.FID13145093]

Thanks, Stan. We appreciate your efforts to push this process forward as quickly as possible and believe we've addressed all of our 278e obligations and all of your team's questions. Our hope is that we can now get the preclearance finalized in very short order.

As for the Senate Questionnaire, we have been informed by the Transition team that they are not authorizing it to be released. If you have questions about that decision, Cindy Berry (who is copied on this e-mail) will be your best resource for additional information.

Stefan and I continued to be available to discuss as needed.

Thanks for your assistance, Ben

<image001.png>

Benjamin P. Keane Managing Associate

D | Fax +1 202 496 7756 D | Fax +1 404 527 4198

ben.keane@dentons.com

Dentons US LLP 1900 K Street, NW, Washington, DC 20006 303 Peachtree Street, NE, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see dentons.comhttp://www.dentons.com/ for Legal Notices.



From: Keane, Benjamin P.

Sent: Tuesday, January 10, 2017 4:47 PM

To: Olesh, Stanley D. (HHS/OGC); Passantino, Stefan C.

Cc: Hall, Randall (HHS/OGC)

Subject: RE: 278 & draft Ethics Agreement [DEN-US_Active.FID13145093]

Stan,


We should be all set on the final item as well. Our team has cross-referenced the records against the info and checked/unchecked the appropriate boxes in the system. Just a few minor changes, but we should be all set to push this thing forward.

Thanks,

Ben

<image001.png>

Benjamin P. Keane Managing Associate



Dentons US LLP 1900 K Street, NW, Washington, DC 20006 303 Peachtree Street, NE, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see dentons.comhttp://www.dentons.com/ for Legal Notices.





	Acienal to 1 ii 10	
	Referral to HHS	
	tolonal to this	
Rest of chair	mentioned above	

From: Patrick J. Lightfoot
To: Heather A. Jones

Subject: RE: Representative Tom Price

Date: Wednesday, January 11, 2017 1:27:59 PM

Thanks!

-----Original Message-----From: Heather A. Jones

Sent: Wednesday, January 11, 2017 1:27 PM To: Patrick J. Lightfoot; Teresa L. Williamson Subject: Fw: Representative Tom Price

Please see below

Sent from my BlackBerry 10 smartphone on the Verizon Wireless 4G LTE network.

Original Message

From: Ann M Donaldson

Sent: Wednesday, January 11, 2017 1:21 PM To: Deborah J. Bortot; Heather A. Jones Subject: Representative Tom Price

On behalf of the President-Elect, this email serves as confirmation that the President-Elect intends to nominate Representative Tom Price to be Secretary of Health and Human Services. Please transmit his pre-cleared 278 report to the appropriate Senate committee.

Ann M. Donaldson Associate JONES DAY® - One Firm Worldwide 51 Louisiana Avenue, NW Washington, DC 20001 Office +1 From: Passantino, Stefan C.

To: Olesh, Stanley D. (HHS/OGC); Keane, Benjamin P.

Cc: Fischmann, Elizabeth (HHS/OGC); Hall, Randall (HHS/OGC); Cindy Berry; Patrick J. Lightfoot

Subject: RE: PRECLEARED: Thomas Price

Date: Wednesday, January 11, 2017 4:09:12 PM

Attachments: image001.png

Yes. I believe it is signed. Let me see and get right back.







Blog: www.paytoplaylawblog.com

Bio I Blog I Website

Chair, **Dentons Political Law** Practice

Dentons US LLP 1900 K Street, NW, Washington, DC 20006

Dentons US LLP 303 Peachtree Street, Suite 5300, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see <u>dentons.com</u> for Legal Notices.



From: Passantino, Stefan C.

Sent: Wednesday, January 11, 2017 2:52 PM


To: Olesh, Stanley D. (HHS/OGC); Keane, Benjamin P.

Cc: Fischmann, Elizabeth (HHS/OGC); Hall, Randall (HHS/OGC); Cindy Berry; Patrick J.

Lightfoot

Subject: RE: PRECLEARED: Thomas Price

Thank you. I very much appreciate the professionalism of the entire HHS staff and you in particular. I will get you an answer as to how we get you the letter.



Dentons US LLP 303 Peachtree Street, Suite 5300, Atlanta, GA 30308

大成 Salans FMC SNR Denton McKenna Long

Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. This email may be confidential and protected by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are prohibited; please notify us immediately and delete this copy from your system. Please see <u>dentons.com</u> for Legal Notices.





From: Patrick J. Lightfoot

Sent: Wednesday, January 11, 2017 12:23 PM

To: 'Ann M Donaldson'

Cc: Hall, Randall (HHS/OGC); Fischmann, Elizabeth (HHS/OGC); Olesh, Stanley D.

(HHS/OGC)

Subject: RE: PRECLEARED: Thomas Price

No attachment found in search

Annie,

Mr. Price's draft ethics agreement is attached.

Sincerely,

--

Patrick J. Lightfoot

Assistant Counsel, Ethics Law & Policy Branch

General Counsel & Legal Policy Division

U.S. Office of Government Ethics

1201 New York Ave NW, Suite 500

Washington, DC 20005

Telephone: (202) 482-9271

Visit OGE's website: <u>www.oge.gov</u>

Follow OGE on Twitter: @OfficeGovEthics

From: Deborah J. Bortot

Sent: Wednesday, January 11, 2017 12:21 PM

To: 'Ann M Donaldson'

Cc: Patrick J. Lightfoot; David J. Apol; Heather A. Jones; Sandra S. Mabry; Keith Labedz; Teresa L. Williamson; Rodrick T. Johnson; Emory A. Rounds III; Hall, Randall (HHS/OGC);

'Fischmann, Elizabeth (HHS/OGC)' **Subject:** PRECLEARED: Thomas Price

Annie, Thomas Price is precleared.

Patrick, please forward the ethics agreement to Annie.

Thanks!

Deb

Deborah J. Bortot

Chief, Presidential Nominations Branch

U.S. Office of Government Ethics

1201 New York Ave., NW, Suite 500

Washington, DC 20005-3917

Telephone: (202) 482-9227

Facsimile: (202) 482-9237

OGE Confidential Notice: This email, including all attachments, may constitute a Federal record or other Government property that is intended only for the use of the individual or entity to which it is addressed. This email also may contain information that is privileged,



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov] **Sent:** Wednesday, January 11, 2017 6:01 PM

To: Olesh, Stanley D. (HHS/OGC)

Subject: RE: FW: PRECLEARED: Thomas Price

Stan,

What's a good number to reach you at? I tried the number you called me on earlier but it said the mailbox wasn't in service.

--Patrick



From: Kris Skrzycki [mailto:kskrzycki@gmail.com] Sent: Wednesday, January 11, 2017 4:23 PM

To: Passantino, Stefan C.; Olesh, Stanley D. (HHS/OGC)

Cc: Keane, Benjamin P.; Cindy Berry

Subject: Re: FW: PRECLEARED: Thomas Price

Stanley, I have a signed copy of the Pre-Clearance letter. I can have it scanned and sent. Who should it be emailed to?

On Wed, Jan 11, 2017 at 4:11 PM, Passantino, Stefan C.

Kris, can you please coordinate and resolve HHS's sense of urgency below? I think this is just logistics.



D (b) (6)
M(b) (6)

Fax: <u>+1 202 496 7756</u>



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov] Sent: Wednesday, January 11, 2017 7:17 PM

To: Fischmann, Elizabeth (HHS/OGC); Olesh, Stanley D. (HHS/OGC)

Subject: RE: Pre-Clearance Letter - Price - HHS

When opening the report, there should be an option to "Sign" the report. After clicking Sign, check the certification that the report is accurate and complete, then scroll to the bottom of the page to click Submit.

If there is a number where we can reach you to walk you through the steps over the phone, we would be happy to do so.

From: tom price Sent: Wednesday, January 11, 2017 6:58 PM

To: Olesh, Stanley D. (HHS/OGC)

Cc: Kris Skrzycki; Patrick J. Lightfoot; Passantino, Stefan C.; Keane, Benjamin P.; Cynthia Berry

Subject: Re: Pre-Clearance Letter - Price - HHS

278e complete and submitted



From: tom price [mailto

Sent: Wednesday, January 11, 2017 5:57 PM

To: Kris Skrzycki; Olesh, Stanley D. (HHS/OGC); pjlightf@oge.gov

Cc: Passantino, Stefan C.; Keane, Benjamin P.; Cynthia Berry

Subject: Re: Pre-Clearance Letter - Price - HHS

I thought a pdf was not acceptable.

Is that not true?

Sent from my BlackBerry 10 smartphone on the Verizon Wireless 4G LTE network.

From: Kris Skrzycki

Sent: Wednesday, January 11, 2017 4:36 PM

To: ; pilightf@oge.gov

Cc: Passantino, Stefan C.; Keane, Benjamin P.; Cynthia Berry; tom price

Subject: Pre-Clearance Letter - Price - HHS

Attached is a pre-clearance letter/ethics agreement signed by Dr. Price, nominee for Secretary of Health and Human Services.

Kris


OGE Confidential Notice: This email, including all attachments, may constitute a Federal record or other Government property that is intended only for the use of the individual or entity to which it is addressed. This email also may contain information that is privileged, confidential, or otherwise protected from disclosure under applicable law. If you are not the intended recipient or the employee or agent responsible for delivering the transmission to the intended recipient, you are hereby notified that any dissemination, distribution, copying or use of this email or its contents is strictly prohibited. If you have received this email in error, please notify the sender by responding to the email and then immediately delete the email.

From: Deborah J. Bortot Teresa L. Williamson To: Cc: Sandra S. Mabry

Subject: FW: Final DAEO Letter and Ethics Agreement for Dr. Thomas E. Price

Date: Wednesday, January 11, 2017 7:55:58 PM

DAEO Ltr to OGE Dr. Thomas E. Price FINAL 1.11.17.pdf Ethics Agreement Dr. Thomas E. Price FINAL 1.11.17.pdf Attachments:



 From:
 Teresa L. Williamson

 To:
 Sandra S. Mabry

 Subject:
 FW: OGE Reports

Date: Thursday, January 12, 2017 11:05:31 AM

Hi Sandy, See Chung's email below. I figure we have one voice from OGE to the committee on questions on the status of reports and I'm assuming that's your voice. Let me know if I should be calling, I'd be happy to do so.

Thanks

Teresa

From: Shek, Chung (HELP Committee)

Sent: Thursday, January 12, 2017 11:03 AM

To: Teresa L. Williamson **Subject:** OGE Reports

Hey Teresa,

Are there any updates as to when we might be getting OGE reports for Price,

ĵ.

Thanks!

Chung

From: Sandra S. Mabry
To: "Ann M Donaldson"

Subject: FW: Public Financial Disclosure Report of Thomas E. Price

Date: Thursday, January 12, 2017 7:12:21 PM

Attachments: Price, Thomas E. final278.pdf

Price, Thomas E. finalEA.pdf

Price, Thomas E. finalsenateltr-HELP--.docx.pdf

inal EA and final senate letter released below. 278 nancial disclosure report withheld in full - (b)(3) - vailable at https://extapps2.oge.gov/201/Presiden.nsf/

Annie,

Yesterday we sent the documents for Dr. Price to the Senate Finance Committee, the committee that handles the nomination for the Secretary of Health and Human Resources. With the email below, we have transmitted the package to the Committee on Health, Education, Labor, and Pensions, consistent with long-time practice. If you have any questions, please call me at 202-482-9258 or Deb at 202-482-9277. Thanks, Sandy

From: Sandra S. Mabry

Sent: Thursday, January 12, 2017 7:01 PM

To: 'Chung_Shek@help.senate.gov'

Cc: Deborah J. Bortot; Teresa L. Williamson; Rodrick T. Johnson; Heather A. Jones; 'Ann M Donaldson'

Subject: Public Financial Disclosure Report of Thomas E. Price

Final EA and final senate letter released below. 278 financial disclosure report withheld in full - (b)(3) - Available at https://extapps2.oge.gov/201/Presiden.nsf/PAS%20Index?OpenView

Good Evening,

I've attached the financial disclosure package for Thomas E. Price. President-Elect Trump has announced his intention to nominate Dr. Price for the position of Secretary, Department of Health and Human Services

The hard copy of the attached documents will be placed at OGE reception for pick up by a Senate rider page per our agreement. If you have any questions, please contact Teresa Williamson @ 202-482-9283.

Please respond to this message to confirm receipt of the attached package, and please let me know in your response whether you will send a Senate rider page.

Thanks!

Sandra Mabry Presidential Nominations Branch U.S. Office of Government Ethics 1201 New York Avenue, NW - Suite 500 Washington, DC 20005 202-482-9258 at ick J lightfood

THE Fendel (HHS/MDG/CT)

RE om 2798 - Udgale et e fo the OGE le of D Tom ice
Tuxciday January 31 2017 7 51 00 AM
mice/C011 cng

Just wanted to follow up and see if you'd heard back from the filer's attorney.

Thanks!



From: Keane Benjamin P 10 16 16 Sent: Monday January 22 2017 3:19 PM
To: Hal Randal (HHS/OGC)
Subject: FW: Form 278e - Update Letter for the OGE Fie of Dr. Tom Pr ce

Thanks for con imming receipt of this document over the phone for me th is a termoon. If you have a second so send an e-mail confirmation of receipt as we lit would be much appreciated. Sorry to ask you to do that, but I'd feel bet er having written documental ion for my records moving forward.

Thanks again and have a great day, Ben

Benjamin P. Keane Managing Associate

| Fax 1 202 96 7756 |
D	10	10	Fax 1 0 275 96 7756		
D	10	10	Fax 1 0 527 198		
D	10	10	10	10	10
D	10	10	10	10	10
D	10	10	10	10	10
D	10	10	10	10	
D	10	10	10	10	
D	10	10	10	10	
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10	10	10		
D	10				

Den ons s a global egal practice providing client serv ces worldwide fitrough its member firms and all lates. This email may be confidential and protect on by legal privilege. If you are not the intended recipient, disclosure, copying, distribution and use are profibe too; please notify us immediately and de ete this copy from your system. Please see de n s.co. for Legal Notices.



From: Patrick J. Lightfoot

To: "Fischmann, Elizabeth (HHS/OGC)"; "Hall, Randall (HHS/OGC)"

Subject: Update on Price Report

Date: Tuesday, January 31, 2017 12:44:35 PM

Hi Elizabeth and Randy,

In light of Congressman Price's testimony at his confirmation hearing that (b)(3), (5), (6)

Please feel free to forward those portions above to him/his attorney and send any response you receive my way. Thank you!

--Patrick

From: Patrick J. Lightfoot

To: "Olesh, Stanley D. (HHS/OGC)"

Cc: "Hall, Randall (HHS/OGC)"; Patrick Shepherd

Subject: RE: ADVANCE -- Price CD request

Date: Wednesday, February 01, 2017 10:47:44 AM

Stan,

I spoke with the head of our CD program and it appears that the best course of action will be to wait until we've resolved the remaining questions surrounding the amendment of the 278 and EA before moving forward with a CD review in case anything needs to be adjusted on that front. Once we're all clear there, we can start the review of the CD.

--Patrick

From: Patrick J. Lightfoot

Sent: Tuesday, January 31, 2017 12:51 PM

To: 'Olesh, Stanley D. (HHS/OGC)' **Cc:** 'Hall, Randall (HHS/OGC)'

Subject: RE: ADVANCE -- Price CD request

Hi Stan,

I can forward this to the manager of our CD program (which might result in the CD being assigned to me anyway), but I'd note that we're still trying to work out the amendment letter and corresponding changes to the ethics agreement, which would prevent the CD from being complete until those are done. I believe Randy was trying to get in touch with his attorney when we spoke about it on Thursday.

--Patrick









From: Keane, Benjamin P.

Sent: Thursday, February 02, 2017 11:22 AM To: Hall, Randall (HHS/OGC)

Cc: Olesh, Stanley D. (HHS/OGC); Fischmann, Elizabeth (HHS/OGC)

Subject: RE: Questions for Dr. Price

Importance: High

Randy,

Thanks for your assistance with these matters. Please find below the nominee's responses to both inquiries.

Sincerely, Ben Keane



Referral to HHS	





From: Patrick J. Lightfoot
To: Elaine Newton

Subject: ADVANCE -- Price CD request

Date: Wednesday, February 08, 2017 8:31:52 AM

Attachments: PriceSec-CD-ogecdtransm.doc

TEP HHS Certificate of Divestiture Request Letter.pdf

Ethics Agreement Dr. Thomas E. Price FINAL 1.11.17.pdf

Price Thomas E. final278.pdf

Price, Thomas final278EAsupplement.pdf

Attachments referred to HHS; 278 not available unde FOIA; Final EA released below

Elaine,

Attached are the materials for Dr. Price's CD request. HHS is requesting a review in advance of his confirmation so that he can then send us official versions of the docs and divest ASAP.

Thanks!

--Patrick



From: Patrick J. Lightfoot

To: "Olesh, Stanley D. (HHS/OGC)"

Cc: Patrick Shepherd; Hall, Randall (HHS/OGC); Fischmann, Elizabeth (HHS/OGC)

Subject: RE: ADVANCE -- Price CD request

Date: Wednesday, February 08, 2017 12:17:24 PM

Hi Stan,

Unfortunately, there isn't a set estimate on turn-around time I can give because every CD package is different.

--Patrick



From: Patrick J. Lightfoot [mailto:pjlightf@oge.gov]
Sent: Wednesday, February 08, 2017 8:29 AM

To: Olesh, Stanley D. (HHS/OGC)

Cc: Patrick Shepherd; Hall, Randall (HHS/OGC) Subject: RE: ADVANCE -- Price CD request

Hi Stan,

Now that we've got the signed amendment letter from Dr. Price, I'll forward the CD package for pre-

review.

Thanks!

--Patrick

Referral to HHS	

From: <u>Teresa L. Williamson</u>

To: Patrick J. Lightfoot; "Subject: Amendment to Public Financial Disclosure Report of Thomas E. Price

Date: Thursday, February 09, 2017 7:57:31 AM

Attachments: Price, Thomas finalagencyltr.pdf

Price, Thomas OGEcoverletteramendment.pdf Price, Thomas final278EAsupplement.pdf Price, Thomas senateAmendFINANCEltr.pdf

Agency letter referred to HHS; other attachments released below

Good Morning,

The attached is an amendment to the final report that was submitted to the committee by letter dated January 11, 2017.

Thanks!

Teresa Williamson US Office of Government Ethics 1201 New York Avenue, NW - Suite 500 Washington, DC 20005 202-482-9283

GOVERNMENT ETHICS

February 8, 2017

The Honorable Orrin Hatch Chairman Committee on Finance United States Senate Washington, DC 20510

Dear Mr. Chairman:

By letter dated January 11, 2017, the Office of Government Ethics (OGE) transmitted to the Committee the financial disclosure report and ethics agreement of Thomas E. Price in connection with his nomination for the position of Secretary, Department of Health and Human Services. Enclosed are a letter from the Department of Health and Human Services and a letter from Dr. Price amending his financial disclosure report and supplementing his ethics agreement.

Dr. Price's enclosed letter amends the following four items that he previously disclosed in his financial disclosure report: (1) "Chattahoochee Associates" ("Organization Name" and "Position Held" columns amended in Part 1, Line 2); (2) "Chattahoochee Associates" ("Description" column amended in Part 2, Line 1); (3) "Amazon Com Inc" ("Value" column amended in Part 6, Line 14.55); and (4) "Innate Immunotherapeutics Ltd." ("Income Type" and "Income Amount" columns amended in Part 6, Line 15.1). Dr. Price's enclosed letter also adds the following new line item entry that he previously omitted from his financial disclosure report: "Innate Immunotherapeutics Ltd." (stock valued at \$100,001-\$250,000 in Part 6, Line 28). Finally, the letter supplements his January 11, 2017, ethics agreement with additional commitments.

We have reviewed this additional submission and have obtained advice from the Department of Health and Human Services concerning any possible conflict in light of its functions and Dr. Price's proposed duties. Based on the information provided, OGE and the Department of Health and Human Services continue to believe that there will be no unresolved conflicts of interest between his financial interests and the duties that he will be expected to perform as Secretary.

Sincerely,

Walter M. Shaub, Jr. Director

Enclosures

GOVERNMENT ETHICS

February 7, 2017

The Honorable Lamar Alexander Chairman Committee on Health, Education, Labor, and Pensions United States Senate Washington, DC 20510

Dear Mr. Chairman:

By letter dated January 11, 2017, the Office of Government Ethics (OGE) transmitted to the Committee the financial disclosure report and ethics agreement of Thomas E. Price in connection with his nomination for the position of Secretary, Department of Health and Human Services. Enclosed are a letter from the Department of Health and Human Services and a letter from Dr. Price amending his financial disclosure report and supplementing his ethics agreement.

Dr. Price's enclosed letter amends the following four items that he previously disclosed in his financial disclosure report: (1) "Chattahoochee Associates" ("Organization Name" and "Position Held" columns amended in Part 1, Line 2); (2) "Chattahoochee Associates" ("Description" column amended in Part 2, Line 1); (3) "Amazon Com Inc" ("Value" column amended in Part 6, Line 14.55); and (4) "Innate Immunotherapeutics Ltd." ("Income Type" and "Income Amount" columns amended in Part 6, Line 15.1). Dr. Price's enclosed letter also adds the following new line item entry that he previously omitted from his financial disclosure report: "Innate Immunotherapeutics Ltd." (stock valued at \$100,001-\$250,000 in Part 6, Line 28). Finally, the letter supplements his January 11, 2017, ethics agreement with additional commitments.

We have reviewed this additional submission and have obtained advice from the Department of Health and Human Services concerning any possible conflict in light of its functions and Dr. Price's proposed duties. Based on the information provided, OGE and the Department of Health and Human Services continue to believe that there will be no unresolved conflicts of interest between his financial interests and the duties that he will be expected to perform as Secretary.

Sincerely,

Walter M. Shaub, Jr. Director

Enclosures



JAN 1 2 2017

The Honorable Lamar Alexander Chairman Committee on Health, Education, Labor, and Pensions United States Senate Washington, DC 20510

Dear Mr. Chairman:

In accordance with the Ethics in Government Act of 1978, I enclose a copy of the financial disclosure report filed by Thomas E. Price. President-Elect Trump has announced his intention to nominate Dr. Price for the position of Secretary, Department of Health and Human Services.

We have reviewed the report and have obtained advice from the agency concerning any possible conflict in light of its functions and the nominee's proposed duties. Also enclosed is an ethics agreement outlining the actions that the nominee will undertake to avoid conflicts of interest. Unless a date for compliance is indicated in the ethics agreement, the nominee must fully comply within three months of confirmation with any action specified in the ethics agreement.

Based thereon, we believe that this nominee is in compliance with applicable laws and regulations governing conflicts of interest.

Sincerely,

Walter M. Shaub, Jr.

Director

Enclosures

January 11, 2017

Ms. Elizabeth J. Fischmann
Associate General Counsel for Ethics
Designated Agency Ethics Official
U.S. Department of Health and Human Services
Room 710-E, Hubert H. Humphrey Building
200 Independence Avenue, SW
Washington, DC 20201

Dear Ms. Fischmann:

The purpose of this letter is to describe the steps that I will take to avoid any actual or apparent conflict of interest in the event that I am confirmed for the position of Secretary, U.S. Department of Health and Human Services.

As required by 18 U.S.C. § 208(a), I will not participate personally and substantially in any particular matter in which I know that I have a financial interest directly and predictably affected by the matter, or in which I know that a person whose interests are imputed to me has a financial interest directly and predictably affected by the matter, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1), or qualify for a regulatory exemption, pursuant to 18 U.S.C. § 208(b)(2). I understand that the interests of the following persons are imputed to me: any spouse or minor child of mine; any general partner of a partnership in which I am a limited or general partner; any organization in which I serve as officer, director, trustee, general partner or employee; and any person or organization with which I am negotiating or have an arrangement concerning prospective employment.

Upon confirmation, I will resign from my position as Managing Partner of Chattahoochee Associates LP. I will continue to have a financial interest in this entity, but I will not provide services material to the production of income. Instead, I will receive only passive investment income from it. I will not participate personally and substantially in any particular matter that to my knowledge has a direct and predictable effect on the financial interests of Chattahoochee Associates LP, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1).

Upon confirmation, I will resign from my position as Delegate of the American Medical Association. For a period of one year after my resignation, I will not participate personally and substantially in any particular matter involving specific parties in which I know the American Medical Association is a party or represents a party, unless I am first authorized to participate, pursuant to 5 C.F.R. § 2635.502(d).

Within 90 days of my confirmation, I will divest my interests in the following entities:

AETNA Inc. Alphabet Inc. Amazon.com Inc.

Ms. Elizabeth J. Fischmann Page 2

American Tower REIT

Amgen Inc.

Apple Inc.

Arch Capital Group Ltd.

Arris International PLC

Athena Health Inc.

Biogen Inc.

Bristol Myers Squibb Co.

Calpine Corp.

CBS Corp.

Cognizant Tech Solutions

Crown Castle Intl Corp.

CVS Health Corp.

Danaher Corp.

Delta Airlines, Inc.

Eli Lilly & Co.

Facebook Inc.

Hewlett Packard, Inc.

Honeywell Corp.

Innate Immunotherapeutics Ltd.

Jazz Pharmaceuticals PLC

Kansas City Southern

L Brands Inc.

Lyondellbasell Industries NV

McKesson Corp.

Nextera Energy Inc.

Northrop Grumman Corp.

PG&E Corp.

Pfizer Inc.

Qihoo 360 Technology Co. Ltd.

Sempra Energy

Starbucks Corp.

Thermo Fisher Scientific, Inc.

Union Pacific Corp.

United Technologies Corp.

Verizon Communications Inc.

Whitewave Foods Corp.

Xerox Corp.

XL Group PLC

Zimmer Biomet Holdings Inc.

With regard to each of these entities, I will not participate personally and substantially in any particular matter that to my knowledge has a direct and predictable effect on the financial interests of the entity

Ms. Elizabeth J. Fischmann Page 3

until I have divested it, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1), or qualify for a regulatory exemption, pursuant to 18 U.S.C. § 208(b)(2).

I will retain limited partnership interests in the following entities that own property rented to healthcare-related tenants (in addition to Chattahoochee Associates, discussed above):

- 1) Diagnostic Ventures of Roswell LLC;
- 2) RMC3, LLC

With regard to each of these entities, I will not participate personally and substantially in any particular matter that to my knowledge has a direct and predictable effect on the financial interests of the entity, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1).

My spouse is employed as a representative in the Georgia state legislature, a position for which she receives a fixed annual salary. I will not participate personally and substantially in any particular matter involving specific parties in which I know the state of Georgia is a party or represents a party, unless, on a case-by-case basis, I am first authorized to participate, pursuant to 5 C.F.R. § 2635.502(d). I will abide by any limitations that are placed on that authorization.

I understand that I may be eligible to request a Certificate of Divestiture for qualifying assets and that a Certificate of Divestiture is effective only if obtained prior to divestiture. Regardless of whether I receive a Certificate of Divestiture, I will ensure that all divestitures discussed in this agreement occur within the agreed upon timeframes and that all proceeds are invested in non-conflicting assets.

In order to avoid potential conflicts of interest during my appointment as Secretary, I, my spouse, or any minor children of mine will not acquire any direct financial interest in entities listed on the FDA prohibited holdings list or in entities involved, directly or through subsidiaries, in the following industries: (1) research, development, manufacture, distribution, or sale of pharmaceutical, biotechnology, or medical devices, equipment, preparations, treatment, or products; (2) veterinary products; (3) healthcare management or delivery; (4) health, disability, or workers compensation insurance or related services; (5) food and/or beverage production, processing or distribution; (6) communications media; (7) computer hardware, computer software, and related internet technologies; (8) wireless communications; (9) social sciences and economic research organizations; (10) energy or utilities; (11) commercial airlines, railroads, shiplines, and cargo carriers; or (12) sector mutual funds that concentrate their portfolios on one country other than the United States. In addition, we will not acquire any interests in sector mutual funds that concentrate in any of these sectors.

Ms. Elizabeth J. Fischmann Page 4

I have been advised that this ethics agreement will be posted publicly, consistent with 5 U.S.C. § 552, on the website of the U.S. Office of Government Ethics with ethics agreements of other Presidential nominees who file public financial disclosure reports.

Sincerely,

Thomas E. Price, M.D.

February 7, 2017

Ms. Elizabeth J. Fischmann
Associate General Counsel for Ethics
Designated Agency Ethics Official
U.S. Department of Health and Human Services
Room 710-E, Hubert H. Humphrey Building
200 Independence Avenue, SW
Washington, DC 20201

Dear Ms. Fischmann:

The purposes of this letter are to amend the financial disclosure report that I signed on December 15, 2016, and to supplement the ethics agreement that I signed on January 11, 2017.

A) Financial Disclosure Report

To correct inadvertent errors in my December 15, 2016, financial disclosure report, the items identified below are amended, as follows:

Part 1

#	Organization Name	City/State	Organization Type	Position Held	From	To
2	Chattahoochee Associates	Atlanta, Georgia	General Partnership	Managing and General Partner	11/1993	Present

Part 2

#	Description	EIF	Value	Income Type	Income Amount
1	Chattahoochee Associates	no	\$100,001-\$250,000		None (or less than \$201)

Part 6

#	Description	EIF	Value	Income Type	Income Amount
14.55	Amazon Com Inc	n/a	None (or less than \$1,001)	Capital Gains	\$2,501-\$5,000
15.1	Innate Immunotherapeutics Ltd. (INNMF)	n/a	\$15,001-\$50,000		None (or less than \$201)

To correct an inadvertent error in my December 15, 2016, financial disclosure report, the following item is added to that financial disclosure report:

Part 6

#	Description	EIF	Value	Income Type	Income Amount
28	Innate Immunotherapeutics Ltd. (INNMF)	n/a	\$100,001-\$250,000		None (or less than \$201)

Ms. Elizabeth J. Fischmann Page 2

With regard to the assets disclosed in my December 15, 2016, financial disclosure report other than those listed above, the U.S. Office of Government Ethics has asked me to confirm that I disclosed the current value at the time of reporting. By this letter, I am confirming that I used current value with regard to those assets. This letter makes no changes to the value categories disclosed in that financial disclosure report other than those indicated above.

B) Supplement to January 11, 2017, Ethics Agreement

The new item listed above (Innate Immunotherapeutics Ltd./\$100,001-\$250,000) is covered by the commitment I made in my January 11, 2017, ethics agreement to divest all interests in Innate Immunotherapeutics Ltd. within 90 days of confirmation. In addition, the following commitments supplement my ethics agreement dated January 11, 2017.

In February 2017, I resigned from my position as Managing and General Partner of Chattahoochee Associates and transferred my ownership interest to my spouse. I will not participate personally and substantially in any particular matter that to my knowledge has a direct and predictable effect on the financial interests of Chattahoochee Associates, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1).

If I have a managed account or otherwise use the services of an investment professional during my appointment, I will ensure that the account manager or investment professional obtains my prior approval on a case-by-case basis for the purchase of any assets other than cash, cash equivalents, investment funds that qualify for the exemption at 5 C.F.R. § 2640.201(a), obligations of the United States, or municipal bonds.

I understand that as an appointee I will be required to sign the Ethics Pledge (Exec. Order no. 13770) and that I will be bound by the requirements and restrictions therein in addition to the commitments I made in the ethics agreement I signed on January 11, 2017.

I have been advised that this supplement to my ethics agreement will be posted publicly, consistent with 5 U.S.C. § 552, on the website of the U.S. Office of Government Ethics with ethics agreements of other Presidential nominees who file public financial disclosure reports. I understand that this letter will also be released as an attachment to my public financial disclosure report.

Sincerely,

Thomas E. Price, M.D.